PK-group | 11. February 2011
Peer review publications for the PK-group since 2000.
2000
1.
Åsberg A, Berg KJ, Hartmann A. Each administration of cyclosporine A
enhances skin microvascular reactivity in renal transplant recipients.
Microvasc Res 2000; 60 (2): 81-90.
2.
Molden E, Åsberg A, Christensen H. CYP2D6 is involved in O-demethylation of
diltiazem – An in vitro study with transfected human liver cells. Eur J Clin
Pharmacol 2000; 56: 575-579.
3.
Breivik, E.K., Bjørnsson, G., and Skovlund, E. A comparison of pain rating scales
by sampling from clinical trial data. Clin. J. Pain 2000; 16: 22-28.
4.
Hernandez, A.M., Fosså, S.D., Brøgger, A., Kat, A., and Skovlund, E.
Chromosome aberrations after etoposide containing cisplatin-based
chemotherapy for malignant germ-cell tumours. Ann. Onco 2000; 11: 897898.
5.
Alfsen, G.C., Thoresen, S.Ø., Kristensen, G.B., Skovlund, E., and Abeler, V.M.
Histopathological subtyping of cervical adenocarcinoma reveals increasing
incidence rates of endometrioid tumors in all age groups. A population based
study with review of all non-squamous cervical carcinomas in Norway from
1966-70, 1976-80, and 1986-90. Cancer 2000; 89: 1291-1299.
6.
Skovlund, E. and Fosså, S.D. PSA-screening i tre norske fylker i 1999. Tidsskr.
Nor. Lægeforen 2000; 120: 2539-2541.
7.
Skarstein, J., Aass, N., Fosså, S.D., Skovlund, E., and Dahl, A.A. Psychological
distress in cancer patients as measured by the Hospital Anxiety and
Depression Scale (HADS) and the EORTC QLQ-C33. J Psychosomatic Res 2000;
49: 27-34.
8.
Lilleby,W., Fosså, S.D., Knutsen, B.H., Abildgaard, A., Skovlund, E., and Lien,
H.H. Computed tomography / magnetic resonance based volume changes of
the primary tumour in prostate assessed in patients with prostate cancer with
or without androgen deprivation. Radiother. Oncol 2000; 57: 195-200.
9.
Laake, K., Vu, P., Andersen, T.I., Erikstein, B., Kåresen, R., Lønning, P.E.,
Skovlund, E., and Børresen-Dale, A-L. Screening breast cancer patients for
ATM mutations found in Norwegian AT patients. Br. J. Cancer 2000; 83: 16501653.
10.
Molden E, Christensen H and Sund RB. Extensive metabolism of diltiazem and
P-glycoprotein mediated efflux of desacetyl-diltiazem by the rat jejunum in
vitro. Drug Metabolism and Disposition 2000; 28: 107-109.
1
PK-group | 11. February 2011
2001
11.
Åsberg A, Midtvedt K, Vassbotn T, Hartmann A. Better microvascular function
on long-term treatment with lisinopril than nifedipine. Nephrol Dial
Transplant, 2001; 16: 1465-1470.
12.
Åsberg A, Holdaas H, Fjeldså E, Hartmann A. Atorvastatin improves
endothelial function in renal transplant recipients. Nephrol Dial Transplant,
2001; 16: 1920-1924.
13.
Åsberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. Bilateral
pharmacokinetic interaction between cyclosporine A and atorvastatin in renal
transplant recipients. Am J Transplant, 2001; 1(4): 382-386.
14.
Molden E, Åsberg A. Metabolic interactions with statins. [Norwegian]. Tidsskr
Nor Lægeforen 2001; 121: 189-193.
15.
Witczak BJ, Åsberg A, Hartmann A. Acute dialysis-dependent renal failure at
the Rikshospital in 1998 [Norwegian]. Tidsskr Nor Lægeforen, 2001; 121:
1216-1219.
16.
Skovlund, E. and Fenstad, G.U. Should we always choose a non-parametric
test when comparing two apparently non-normal distributions? J. Clin.
Epidemiol 2001; 54: 86-92.
17.
Lilleby, W., Paus, E., Skovlund, E., and Fosså, S.D. Prognostic value of
neuroendocrine serum markers and PSA in irradiated patients with pN0
localized prostate cancer. The Prostate 2001; 46: 126-133.
18.
Fodstad, Ø., Faye, R., Høifødt, H.K., Skovlund, E., Aamdal, S. Immunobeadbased detection and characterization of circulating tumor cells in melanoma
patients. Rec. Res. in Cancer Res 2001; 158: 40-50.
19.
Skovlund, E. Hva kjennetegner en god legemiddelutprøvning? Tidsskr. Nor.
Lægeforen 2001; 121: 336-338.
20.
Breivik, E.K. and Skovlund, E. (Comparing pain rating scales in clinical trials
(letter). Clin. J. Pain 2001; 17: 104-105.
21.
Lilleby, W. Torlakovic, G., Torlakovic, E., Skovlund, E., and Fosså, S.D.
Prognostic significance of histologic grading in patients with prostate
carcinoma who are assessed by the Gleason and World Health Organization
grading systems in needle biopsies obtained prior to radiotherapy. Cancer
2001; 92: 311-319.
22.
Holm, R., Skovlund, E., Skomedal, H., Flørenes, V.A., and Tanum, G. Reduced
expression of p21WAF1 is an indicator of malignant behaviour in anal
carcinomas. Histopathology 2001; 39: 43-49.
2
PK-group | 11. February 2011
23.
Røtterud, R., Berner, Å., Holm, R., Skovlund, E., and Fosså, S.D. p53, p21 and
mdm2 expression versus response to radiotherapy in transitional carcinoma
of the bladder. BJU International 2001; 88: 202-208.
24.
Hall, K.S., Wiklund, T., Erikstein, B., Holte. H., Kvalheim, G., Sommer, H.H.,
Andersen, A., Skovlund, E., Bergh, J., and Hall, C. Effects of dose-intensive
chemotherapy and radiotherapy on serum N-terminal proatrial natriuretic
peptide in high-risk breast cancer patients. Breast Cancer Res & Treat 2001;
67: 235-244.
25.
Suo, Z., Yang, H., Mei, Q., Skovlund, E., Cui, J., and Nesland, J.M. Type 1
protein tyrosine kinases in Chinese breast carcinomas: A clinicopathological
study. Int. J. Surg. Pathol 2001; 9: 177-187.
26.
Røtterud, R., Skomedal, H., Berner, Å., Danielsen, H.E., Skovlund, E., and
Fosså, S.D. p53 and p21 WAF1/CIP1 behave differently in euploid vs aneuploid
bladder tumours treated with radiotherapy. Acta Oncologica 2001; 40: 644652.
27.
Alfsen, G.C., Kristensen, G.B., Skovlund, E., Pettersen, E., and Abeler, V.M.
Histologic subtype has minor importance for overall survival in patients with
adenocarcinoma of the uterine cervix: A population based study of prognostic
factors in 505 patients with nonsquamous cell carcinomas of the cervix.
Cancer 2001; 92: 2471-2483.
28.
Fosså, S.D., Eri, L.M., Skovlund, E., Tveter, K., Vatten, L. No randomized trial of
prostate cancer screening in Norway. Lancet Oncol 2001; 2: 741-745.
2002
29.
Molden E, Åsberg A, Christensen H. Desacetyl-diltiazem (M1) displays several
fold higher affinity to CYP2D6 compared to CYP3A4. Drug Metabolism and
Disposition, 2002; 30(1): 1-3.
30.
Øie E, Yndestad A, Robins S, Bjørnerheim R, Åsberg A, Attramadal H. Early
intervention with a potent endothelin-A/endothelin-B receptor antagonist
aggravates left ventricular remodeling after myocardial infarction in rats. Basic
Res Cardiol 2002; 97: 239-247.
31.
Hermann M, Åsberg A, Rebusaet JLE, Sæther S, Berg KJ, Christensen H. Intake
of grapefruit juice alters the metabolic pattern of cyclosporine A in renal
transplant recipients. Int J Clin Pharmacol Ther 2002; 40(10): 451-456.
32.
Christensen H, Åsberg A, Holmboe ÅB, Berg KJ. Coadministration of grapefruit
juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin
Pharmacol 2002; 58: 515-520.
33.
Molden E, Johansen PW, Bøe GH, Bergan S, Christensen H, Rugstad HE,
Rootwelt H, Reubsaet L, Lehne G. Pharmacokinetics of diltiazem and its
3
PK-group | 11. February 2011
metabolites in relation to CYP2D6 genotype. Clin Pharmacol Ther 2002; 72:
333-42.
34.
Suo, Z., Risberg, B., Kalsson, M.G., Willman, K., Tierens, A., Skovlund, E., and
Nesland, J.M. EGFR family expression in breast carcinomas. c-erbB-2 and cerbB-4 receptors have different effects on survival. J. Pathol 2002; 196: 17-25.
35.
Sandven, P., Qvist, H., Skovlund, E., and Giercksky, K.E. Significance of Candida
recovered from intraoperative specimens in patients with intra-abdominal
perforations. Crit Care Med 2002; 30: 541-547.
36.
Bretthauer, M., Thiis-Evensen, E., Huppertz-Hauss, G., Gisselsson, L., Grotmol,
T., Skovlund, E., and Hoff, G. NORCCAP (NORwegian Colorectal CAncer
Prevention): a randomised trial to assess the safety and efficacy of carbon
dioxide versus air insufflation in colonoscopy. Gut 2002; 50: 604-607.
37.
Puska, P., Korpelainen, V., Høie, L., Skovlund, E., Lahti, T., and Smerud, K.T.
Soy protein in hypercholesterolemia: A double blind, placebo controlled trial.
Eur. J. Clin. Nutr 2002; 56: 352-357.
38.
Bretthauer, M., Gondal, G., Larsen, I.K., Carlsen, E., Eide, T.J., Grotmol, T.,
Skovlund, E., Tveit, K.M., Vatn, M.H., and Hoff, G. Design, organisation and
management of a controlled population screening study for detection of
colorectal neoplasia. Attendance rates in the NORCCAP study (Norwegian
Colorectal Cancer Prevention). Scand J Gastroenterol 2002; 37: 568-573.
39.
Fosså, S.D. and Skovlund, E. Selection of patients may limit the generalizability
of results from cancer trials. Acta Oncol 2002; 41: 131-137.
40.
Heimdal, K., Skovlund, E., Møller, P. Oral contraceptives and risk of familial
breast cancer. Cancer Detection and Prevention 2002; 26: 23-27.
41.
Lund, K., Refsnes, M., Ramis, I., Dunster, C. Boe, J., Schwarze, P.E., Skovlund,
E., Kelly, F.J., and Kongerud, J. Human exposure to hydrogen fluoride induces
acute neutrophilic, eicosanoid, and antioxidant changes in nasal lavage fluid.
Inhalation Toxicology 2002; 14: 119-132.
42.
Suo, Z., Risberg, B., Kalsson, M.G., Willman, K., Skovlund, E., and Nesland, J.M.
The expression of EGFR family ligands in breast carcinomas. Int. J. Surg. Pathol
2002; 10: 91-99.
43.
Hollender, Å., Kvaløy, S., Nome, O., Skovlund, E., Lote, K., and Holte, H. Central
nervous system involvement following diagnosis of non-Hodgkin's lymphoma.
A risk model. Ann. Oncol 2002; 13: 1099-1107.
44.
Søreide, J.A., Varhaug, J.E., Fjøsne, H.E., Erikstein, B, Jacobsen, A.-B., Skovlund,
E., and Kvinnsland, S. Adjuvant endocrine treatment (goserelin vs tamoxifen)
in pre-menopausal patients with operable node positive stage II breast
cancer. A prospective randomized national multicenter study. Eur J Surg Oncol
2002; 28: 505-510.
4
PK-group | 11. February 2011
45.
Bretthauer, M., Hoff, G., Thiis-Evensen, E., Grotmol, T., Thorp Holmsen, S.,
Moritz, V., and Skovlund, E Carbon dioxide insufflation reduces discomfort
due to flexible sigmoidoscopy in colorectal cancer screening. Scand J
Gastroenterol 2002; 37: 1103-1107.
46.
Lindbæk, M. and Skovlund, E. Kontrollerte kliniske forsøk – jakten på sann
effekt av behandling. Tidsskr Nor Lægeforen 2002; 122: 2631-2635.
47.
Bretthauer, M., Hoff, G., Thiis-Evensen, E., Grotmol, T., Larsen, I.K., Kjellevold,
Ø., and Skovlund, E. Use of a disposable sheath system for flexible
sigmoidoscopy in decentralized colorectal cancer screening. A randomised
controlled trial. Endoscopy 2002; 34: 814-818.
48.
Sundstrøm, S., Bremnes, R.M., Kaasa, S., Aasebø, U., Hatlevoll, R., Dahle, R.,
Boye, N., Wang, M., Vigander, T., Vilsvik, J., Skovlund, E., Hannisdal, E., and
Aamdal, S. Cisplatin and etoposide regimen is superior to cyclophosphamide,
epirubicin and vincristine regimen in small-cell lung cancer: Results from a
randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002; 20: 46654672.
49.
Hermann M, Christensen H and Reubsaet JLE. Evaluation of essential
parameters in the chromatographic determination of cyclosporine A and
metabolites using a D-optimal design. J. Pharm. Biomed. Anal. 2002; 30: 12631276.
2003
50.
Åsberg A. Interactions between cyclosporine A and lipid-lowering drugs:
Implications for organ transplant recipients. Drugs 2003; 63(4): 367-378.
51.
Åsberg A, Holdaas H, Jardine AG, Edvardsen C, Hartmann A. Fluvastatin
reduces atherogenic lipids without any effect on native endothelial function
early after kidney transplantation. Clin Transpl 2003; 17(4): 385-390.
52.
Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Åsberg A, Degré M,
Fauchald P, Rollag H. Pre-emptive therapy of CMVpp65 antigen positive renal
transplant recipients with oral ganciclovir: a randomised, comparative study.
Nephrol Dial Transplant 2003; 18(9): 1899-1908.
53.
Molden E, Bøe GH, Christensen H, Reubsaet L. Development of a highperformance liquid chromatography-mass spectrometry method for analyzing
diltiazem and 11 of its phase I metabolite in human plasma. J Pharm Biomed
Anal 2003; 33: 275-85.
54.
Wangensteen H, Molden E, Christensen H, Malterud KE. Isolation and
characterisation of CYP3A4 inhibitors in grapefruit peel. Eur J Clin Pharmacol
2003; 58: 663-68.
5
PK-group | 11. February 2011
55.
Torlakovic, E., Skovlund, E., Snover, D. L., Torlakovic, G., and Nesland, J.M.
Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 2003;
27: 65-81.
56.
Moe, T.J., Mykletun, A.., Matre, R., Skovlund, E., Bassøe, C.F., and Dahl, A.A.
Change of immunoglobulins and complement factors in patients with selfinjurious behaviour. Acta Psychiatr Scand 2003; 107: 151-154.
57.
Diep, C.B., Thorstensen, L., Meling, G.I., Skovlund, E., Rognum, T.O., and
Lothe, R.A. Genetic tumor markers with prognostic impact in Dukes’ stages B
and C colorectal cancer patients. J Clin Oncol 2003; 21: 820-829.
58.
Guren, M.G., Dueland, S., Skovlund, E., Fosså, S.D., Poulsen, J.P., and Tveit,
K.M. Quality of life during radiation therapy for rectal cancer. Eur J Cancer
2003; 39: 587-594.
59.
Rønning, M., Blix, H.S., Strøm, H., Skovlund, E., Andersen, M., and
VanderStichele, R. Problems in collecting comparable national drug use data
in Europe: the example of antibacterials. Eur J Clin Pharmacol 2003; 58: 843849.
60.
Soucek, P., Gut, I., Trneny, M., Skovlund, E., Grenaker Alnæs, G., Kristensen,
T., Børresen-Dale, A-L., and Kristensen, V.N. Multiplex single-tube screening
for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin’s
and non-Hodgkin’s lymphoma patients of Slavic origin. Eur J Human Genetics
2003; 11: 416-419.
61.
Smeland, S., Aas, M., Skovlund, E., Erikstein, B., Hess, S.L., and Fosså, S.D. Role
of Strontium-89 as adjuvant to palliative external beam radiation is
questionable: results of a double-blind randomised study. Int J Radiation
Oncol Biol Phys 2003; 56: 1397-1404.
62.
Bretthauer, M., Hoff, G., Thiis-Evensen, E., Huppertz-Hauss, G., and Skovlund,
E. Air and carbon dioxide volumes insufflated during colonoscopy.
Gastrointestinal Endoscopy 2003; 58: 203-206.
63.
Breen, A.B., Vaskinn, T.E., Reikvam, Å., Skovlund, E., Lislevand, H., and
Madsen, S. Warfarinbehandling og blødninger (Oral anticoagulants and
bleeding). Tidsskr Nor Lægeforen 2003; 123: 1835-1837.
64.
Madsen, S., Breen, A.B., Vaskinn, T.E., Reikvam, Å, Skovlund, E., and Lislevand,
H. High INR-values responsible for adverse events (eletter). Rapid response to
Odén and Fahlén, BMJ 2003; 325: 1073-1075.
65.
Skovlund, E. Interim analyses in clinical trials. Heart Drug 2003; 3: 113-116.
66.
Hoff, G., Bretthauer, M., Skovlund, E., and Grotmol, T. Re: Baseline findings of
the Italian multicenter randomized controlled trial of “Once-only
sigmoidoscopy” – SCORE (letter). JNCI 2003; 95: 1089-1090.
6
PK-group | 11. February 2011
67.
Reed, W., Hannisdal, E., Skovlund, E., Thoresen, S.Ø., Lilleng, P., and Nesland,
J. Pregnancy and breast cancer: a population based study. Virchows Archiv
2003; 443: 44-50.
68.
Hernes, E., Fosså, S.D., and Skovlund, E. Androgen-independent prostate
cancer: The clinical problem of a growing pelvic tumour. Acta Oncol 2003; 42:
749-755.
69.
Bretthauer, M., Skovlund, E., Grotmol, T., Thiis-Evensen, E., Gondal, G.,
Huppertz-Hauss, G., Efskind, P., Hofstad, B., Holmsen, S.T., Eide, T.J., and Hoff,
G. Inter-endoscopist variation in polyp and neoplasia pick-up rates in flexible
sigmoidoscopy screening for colorectal cancer. Scand J Gastroenterol 2003;
38: 1268-1274.
2004
70.
Åsberg A and Holdaas H Fluvastatin and fluvastatin extended release: a clinical
and safety profile. Expert Rev Cardiovasc Ther 2004; 2(5): 641-652.
71.
Hermann M, Åsberg A, Christensen H, Holdaas H, Hartmann A, Reubsaet JLE.
Substantially elevated levels of atorvastatin and metabolites in cyclosporine A
treated renal transplant recipients. Clin Pharm Ther 2004; 76(4): 388-391.
72.
Molden E. P-glycoprotein - a pump of significance for drug response [in
Norwegian]. Tidsskr Nor Lægeforen 2004; 124: 2921-3.
73.
Molden E. Variability in cytochrome P450-mediated metabolism of
cardiovascular drugs: Clinical implications and practical attempts to avoid
potential problems. Heart Drug 2004; 4: 55-79.
74.
Væth, M. and Skovlund, E. A simple approach to power calculations in
regression models. Statist Med 2004; 23: 1781-1792.
75.
Puska, P., Korpelainen, V., Høie, L., Skovlund, E., and Smerud, K.T. Isolated
soya protein with standardised levels of isoflavones, cotyledon soya fibres and
soya phospholipids improves plasma lipids in hypercholesterolemia: a double
blind, placebo- controlled trial of a yoghurt formulation. Br J Nutr 2004; 91:
393-401.
76.
Wyller, T.B., and Skovlund, E. Korrelerte parametre og annen språklig
slendrian. (Språkspalten) Tidsskr Nor Lægeforen 2004; 124: 973.
77.
Faye, R.S., Aamdal, S., Høifødt, H.K., Jacobsen, E., Holstad, L., Skovlund, E., and
Fodstad, Ø. Immunomagnetic detection and clinical significance of
micrometastatic tumor cells in malignant melanoma patients. Clinical Cancer
Research 2004; 10: 4134-4139.
2005
7
PK-group | 11. February 2011
78.
Hjelmesæth J, Åsberg A, Müller F, Jenssen T, Hartmann A. New-onset
posttransplantation diabetes mellitus: Insulin resistance or insulinopenia?
Impact of immunosuppressive drugs, hepatitis C virus and cytomegalovirus
infection. Current Diabetes Reviews 2005; 1(1): 1-10.
79.
Carlsson KC, Hoem NO, Glauser T, Vinks AA. Development of a population
pharmacokinetic model for carbamazepine based on sparse therapeutic
monitoring data from pediatric patients with epilepsy. Clin Ther 2005; 27(5):
618-26.
80.
Voytovich MH, Simonsen C, Jenssen T, Åsberg A, Midtvedt K, Hjelmesaeth J,
Hartmann A. Short term treatment with rosiglitazone improves glucose
disposal rate and endothelial function in renal transplant recipients with
glucose intolerance. Nephrol Dial Transplant 2005; 20: 413-418.
81.
Hermann M, Åsberg A, Christensen H, Reubsaet JLE, Holdaas H, Hartmann A.
Atorvastatin does not affect pharmacokinetics of cyclosporine in renal
transplant recipients. Eur J Clin Pharmacol 2005; 61: 59-62.
82.
Hermann M, Christensen H, Reubsaet JL. Determination of atorvastatin and
metabolites in human plasma with solid-phase extraction followed by LCtandem MS. Anal Bioanal Chem. 2005; 382(5): 1242-9.
83.
Molden E, Garcia BH, Braathen P, Egge AE. Co-prescription of cytochrome
P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective
analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol.
2005; 61(2): 119-25.
84.
Molden E, Braathen P. Celecoxib is often combined with cytochrome P450
2D6 substrates in general clinical practice. Clin Pharmacol Ther. 2005; 78(1):
93.
85.
Lemahieu WPD, Hermann M, Åsberg A, Verbeke K, Holdaas H, Vanrenterghem
Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors:
No interaction with tacrolimus. Am J Transplant 2005; 5: 2236-2243.
86.
Hjelmesæth J, Åsberg A, Hartmann A, Jenssen T. New-onset diabetes mellitus
after renal transplantation: diagnosis and treatment. Int Diabetes Monitor
2005; 5 (17): 15-21.
87.
Thorsen, L., Skovlund, E., Strømme, S.B., Hornslien, K., Dahl, A.A., and Fosså,
S.D. Effectiveness of physical activity on cardiorespiratory fitness and healthrelated quality of life in young and middle-aged cancer patients shortly after
chemotherapy. J Clin Oncol 2005; 23: 2378-2388.
88.
Skovlund, E., Bretthauer, M., Grotmol, T., Larsen, I.K., and Hoff, G. Sensitivity
of pain rating scales in an endoscopy trial. Clin. J. Pain 2005; 21: 292-296.
89.
Torlakovic, G., Torlakovic, E., Skovlund, E., Nesland, J.M., Reith, A., and
Danielsen, H.E. Volume-related Sequence of Tumor Distribution Pattern in
8
PK-group | 11. February 2011
Prostate Carcinoma: Importance of Posterior Midline Crossover in Predicting
Tumor Volume, Extracapsular Extension, and Seminal Vesicle Invasion.
Croatian Medical Journal 2005; 46: 429-35.
90.
Lund, K., Dunster, C., Ramis, I., Sandstrøm, T., Kelly, F.J., Søstrand, P.,
Schwarze, P.E., Skovlund, E., Boe, J., Kongerud, J., and Refsnes, M. Changes in
inflammatory markers in bronchoalveolar lavage fluid from human volunteers
2 hours after hydrogen fluoride exposure. Hum Exp Toxicol 2005; 24: 1-8.
2006
91.
Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. Prediction of plasma
protein binding displacement and its implications for quantitative assessment
of metabolic drug-drug interactions from in vitro data. J Pharm Sci. 2006;
95(12): 2778-87.
92.
Åsberg A. Interacciones bilaterales entre ciclosporina A y tratamientos
hipolipemiantes – The bilateral interactions between cyclosporine A and lipidlowering therapies. Salud i Ciencia 20. February 2006;
http://www.siicsalud.com.
93.
Holdaas H, Hagen E, Åsberg A, Lund K, Hartmann A, Vaidyanathan S, Prasad P,
He YL, Yeh CM, Bigler H, Rouilly M, Denouel J. Evaluation of pharmacokinetic
interaction between fluvastatin XL and cyclosporine in renal transplant
recipients. Int J Clin Pharm Ther 2006; 44(4): 163-171.
94.
Hermann M, Kase ET, Molden E, Christensen H. Evaluation of microsomal
incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a
statistical experimental design. Curr Drug Metab. 2006; 7(3): 265-71.
95.
Voytovich MH, Åsberg A, Hjelmesæth J, Jenssen T, Hartmann A. Association
between insulin resistance and endothelial dysfunction in renal transplant
recipients. Clin Transplant 2006; 20(2): 195-199.
96.
Hermann M, Bogsrud M, Molden E, Åsberg A, Mohebi BU, Ose L, Retterstøl K.
Exposure of atorvastatin is unchanged while lactone and acid metabolites are
several-fold increased in patients with atorvastatin-induced myopathy. Clin
Pharm Ther 2006; 79: 532-539.
97.
Åsberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisæter AV,
Johnsen LF, Fauchald P, Hartmann A. Calcineurin inhibitor-avoidance with
daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo
kidney transplant recipients. Transplantation 2006; 82(1): 62-68.
98.
Åsberg A, Hjelmesæth J, Voytovich MH, Hartmann A. Endothelial function in
renal transplant recipients is associated with circulating nitric oxide, ACE
inhibitor use and time after transplantation. Vasc Dis Prevent 2006; 3: 229234.
9
PK-group | 11. February 2011
99.
Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable
number of cigarettes on the interaction with olanzapine and clozapine. Eur J
Clin Pharmacol 2006; 62: 1049-53.
100. Hendset M, Rudberg I, Haslemo T, Refsum H, Molden E. The complexity of
active metabolites in therapeutic drug monitoring of psychotropic drugs.
Pharmacopsychiatry 2006; 39: 121-7.
101. Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of
aripiprazole and the active metabolite dehydroaripiprazole in psychiatric
patients. Ther Drug Monit 2006; 28: 744-49.
102. Rudberg I, Hendset M, Uthus LH, Molden E, Refsum H. Heterozygous mutation
in CYP2C19 significantly increases the concentration/dose ratio of racemic
citalopram and escitalopram. Ther Drug Monit 2006; 28: 102-5.
103. Drageset, V., Nesland, J.M., Erikstein, B., Skovlund, E., Sommer, H., Anker, G.,
Wist, E., Lundgren, S., Bergh, J., and Kvalheim, G. Monitoring of disseminated
tumor cells in bone marrow in high-risk breast cancer patients treated with
high-dose chemotherapy. Int. J. Cancer 2006; 118: 2877-2881.
2007
104. Åsberg A, Hansen CN, Reubsaet JLE. Determination of ganciclovir in different
matrices from solid organ transplanted patients treated with a wide range of
concomitant drugs. J Pharm Biomed Anal 2007; 43: 1039-1044.
105. Hjelmesæth J, Hagen LT, Åsberg A, Midtvedt K, Størset Ø, Halvorsen CE,
Mørkrid L, Hartmann A, Jenssen T. The impact of short-term cyclosporine A
treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial
Transpl, 2007; 22: 1743-1749.
106. Falck P, Guldseth H, Åsberg A, Midtvedt K, Reubsaet, JL. Determination of
cyclosporine (CsA) and its six main metabolites in isolated T-lymphocytes and
whole blood using liquid chromatography-tandem mass spectrometry (LCMS/MS). J Chrom B 2007; 852: 345-352.
107. Åsberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz M, Sgarabotto D,
Tuncer M, Noronha I, Hartmann A. A randomized multicenter study of the
safety and efficacy of oral valganciclovir versus intravenous ganciclovir for the
treatment of cytomegalovirus disease in solid organ transplant recipients: The
VICTOR study. Am J Transpl 2007; 7: 2106-2113.
108. Molden E, Spigset O. Fruit and berries – interactions with drugs. Tidsskr Nor
Laegeforen. 2007; 127(24): 3218-20.
109. Molden E, Andersson KS, Jacobsen D. Interactions between statins and
macrolide antibiotics. Tidsskr Nor Laegeforen. 2007; 127(12): 1660-1.
10
PK-group | 11. February 2011
110. Westergren T, Johansson P, Modlen E. Probable warfarin-simvastatin
interaction. Ann Pharmacother. 2007; 41(7): 1292-5.
111. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after
coadministration of macrolide antibiotics in two patients. Pharmacotherapy.
2007; 27(4): 603-7.
112. Molden E, Westergren T. Interaction risk with statin switch. Tidsskr Nor
Laegeforen. 2007; 127(4): 428-31.
113. Hendset M, Hermann M, Refsum H, Molden E. Impact of CYP2D6 genotype on
steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Eur J Clin Pharmacol 2007; 63: 1147-51.
114. Thorsen, L., Dahl, A.A., Skovlund, E., Hornslien, K, and Fosså S.D. Effectiveness
after 1 year of a short-term physical activity intervention on cardiorespiratory
fitness in cancer patients. Letter. J Clin Oncol 2007; 25: 1301-1302.
115. Skovlund, E. Adaptive trial design and its role in oncology: An EMEA
perspective. Eur J Cancer Supplements 2007; 5 (9): 43-44.
2008
116. Falck P, Vethe NT, Åsberg A, Midtvedt K, Bergan S, Reubsaet, JL, Holdaas H.
Cinacalcet influence the pharmacokinetics of tacrolimus but not cyclosporine
or mycophenolate in stable renal transplant recipients. Nephrol Dial
Transplant 2008; 23: 1048-1053.
117. Falck P, Åsberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet, JL, Pfeffer P,
Hartmann A, Midtvedt K. Declining intracellular T-lymphocyte concentration
of cyclosporine A precedes acute rejection in kidney transplant recipients.
Transplantation 2008; 85: 179-184.
118. Skottheim IB, Gedde-Dahl A, Hejazifar S, Åsberg A. Statin lactone forms induce
myotoxicity at lower concentrations compared to respective acid form. Eur J
Pharm Sci 2008; 33: 317-325.
119. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or
atorvastatin interactions with CYP3A4 inhibitors. Drug Saf. 2008; 31(7): 58796.
120. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the
ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in
psychiatric patients. Clin Pharmacol Ther 2008; 83(2): 322-7.
121. Bruheim K, Svartberg J, Carlsen E, Dueland S, Haug E, Skovlund E, Tveit KM,
Guren MG. Radiotherapy for rectal cancer is associated with reduced serum
testosterone and increased FSH and LH. Int J Radiat Oncol Biol Phys 2008;
70(3): 722-7.
11
PK-group | 11. February 2011
122. Dalgard O, Bjøro K, Ring-Larsen H, Bjørnsson E, Holberg-Petersen M, Skovlund
E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A,
Florholmen J, Verbaan H: North-C Group. Pegylated interferon alfa and
ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2
or 3 and rapid virological response. Hepatology 2008; 47(1): 35-42.
123. Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of
sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in
psychiatric patients. Eur J Clin Pharmacol 2008; 64(12): 1181-1188.
124. Falck P, Åsberg A, Byberg KT, Bremer S, Bergan S, Reubsaet JLE, Midtvedt K.
Reduced elimination of cyclosporine A in elderly (>65) kidney transplant
recipients. Transplantation 2008; 86: 1379-1383.
125. Kamal Z, Nordstad MG, Molden E. A 60-year-old man with heart failure, dry
cough and elevated INR values. Tidsskr Nor Legeforen 2008, 128(15): 1679.
126. Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of
sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in
psychiatric patients. Eur J Clin Pharmacol 2008; 64(12):1181-8.
127. Spigset O, Molden E. Cytochrome P-450 3A4--the most important arena for
drug interactions in the body. Tidsskr Nor Legeforen 2008; 128(24): 2832-5.
2009
128. Humar A, Åsberg A, Kumar D, Hartmann A, Moussa G, Jardine AG, Rollag H,
Pescovitz MD. An assessment of herpesvirus co-infection in patients with CMV
disease: correlation with clinical and virologic outcomes. Am J Transplant
2009; 9: 374-381.
129. Falck P, Fiane AE, Geiran OR, Åsberg A. Individual differences in cyclosporine A
pharmacokientics and its association with acute renal function following heart
transplantation. Open Transplant J 2009; 3: 9-13.
130. Åsberg A, Jardine AG, Humar A, Rollag H, Pescovitz MD, Mouas H, Bignamini
A, Töz H, Dittmer I, Montejo M, Hartmann A. Long-term outcomes after
treatment of CMV disease with valganciclovir versus IV ganciclovir in solid
organ transplant recipients: the VICTOR study. Am J Transplant 2009; 9: 12051213.
131. Amundsen R, Åsberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A,
Midtvedt K. Rimonabant affects cyclosporine A, but not tacrolimus
pharmacokinetics in renal transplant recipients. Transplantation 2009; 87(8):
1221-1224.
132. Åsberg A, Midtvedt K, Voytovich MH, Line PD, Narverud J, Reisæter AV,
Mørkrid L, Jenssen T, Hartmann A. Calcineurin inhibitor effects on glucose
12
PK-group | 11. February 2011
metabolism and endothelial function following renal transplantation. Clin
Transplant 2009; 23: 511-518.
133. Høyem S, Bruheim S, Mælandsmo G, Olberg DE, Brudeli B, Åsberg A,
Klaveness J, Rongved P. Didanosine ester prodrugs: synthesis, albumin binding
properties and pharmacokinetic studies in rats. Eur J Med Chem 2009; 44:
3874-3879.
134. Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesæth J, Jenssen
T, Reubsaet JLE, Sandbu R and Åsberg A. Significantly altered systemic
exposure of atorvastatin acid following gastric bypass surgery in morbidly
obese patients. Clin Pharm Ther 2009, 86(3): 311-318.
135. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Åsberg A, Ives J,
Hartmann A, Humar A. Cytomegalovirus resistance in solid organ transplant
recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir
Ther, 2009; 14(5): 697-704.
136. Falck P, Midtvedt K, Van LTT, Storehagen L, Holdaas H, Hartmann A, Åsberg A.
A population pharmacokinetic model of cyclosporine A applicable for assisting
dose management of kidney transplant recipients. Clin Pharmacokinetics
2009; 48(9): 615-623.
137. Manuel O, Åsberg A, Pang X, Hartmann A, Emery VC, Preiksaitis JK, Kumar D,
Pescovitz MD, Bignamini AA, Rollag H, Jardine AG, Humar A. Impact of genetic
polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ
transplant recipients with cytomegalovirus disease. Clin Inf Dis 2009; 49(8):
1160-1166.
138. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M.
Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of
cytochrome B5. Drug Metab Dispos 2009; 37(2): 254-258.
139. Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and
CYP3A4 inhibitors before and after introduction of new reimbursement policy.
Br J Clin Pharmacol 2009; 67(2): 234-241.
140. Molden E, Spigset O. Tobacco smoking and drug interactions [in Norwegian].
Tidsskr Nor Lægeforen 2009; 129: 632-3.
141. Christensen H, Mathiesen L, Postvoll LW, Winther B, Molden E. Different
enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from
human and insect sources. Drug Metab Pharmacokinet 2009; 24: 261-8.
142. Rudberg I, Reubsaet JL, Hermann M, Refsum H, Molden E. Identification of a
novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug
Metab Dispos 2009; 37: 2340-8.
13
PK-group | 11. February 2011
143. Juliebø, V., Bjøro, K., Ranhoff, A., Krogseth, M., Skovlund, E., and Wyller, T.B.
Risk factors for preoperative and postoperative delirium in elderly patients
with hip fracture. J Am Geriatrics Soc 2009; 57: 1354-13.61.
144. Skovlund, E. (2009) Statisticians in regulatory agencies. Pharm Stat. 8, 259263.
145. Hoff, G., Grotmol, T., Skovlund, E., and Bretthauer, M. Risk of colorectal
cancer seven years after flexible sigmoidoscopy screening: randomized trial.
BMJ 2009; 338: b1846 doi:10.1136/bmj.b1846.
146. Waade RB, Christensen H, Rudberg I, Refsum H and Hermann M. Influence of
comedication on serum concentrations of aripiprazole and
dehydroaripiprazole. Ther Drug Monit. 2009; 31 (2): 233-238.
2010
147. Loftheim H, Nguyen, TD, Malerød, H, Lundanes E, Åsberg A, Reubsaet, L. 2-D
hydrophilic interaction liquid chromatography-RP separation in urinary
proteomics – Minimizing variability through improved downstream workflow
compatibility. J Sep Sci 2010; 33: 864-872.
148. Åsberg A, Falck P, Undset LH, Dørje C, Holdaas H, Hartmann A, Midtvedt K.
Computer assisted cyclosporine dosing performs better than traditional
dosing in renal transplant recipients. Ther Drug Monit 2010; 32(2): 152-158.
149. Kotton CN, Kumar D, Caliendo A, Åsberg A, Chou S, Snydman DR, Allen U,
Humar A. International consensus guidelines on the management of
cytomegalovirus in solid organ transplantation. Transplantation 2010;
89(7):779-795.
150. Åsberg A, Rollag H, Hartmann A. Valganciclovir for the prevention and
treatment of CMV in solid organ transplant recipients. Exp Opinion
Pharmacother 2010; 11(7): 1159-1166.
151. Skottheim IB, Jakobsen GS, Stormark K, Christensen H, Hjelmesæth J, Jenssen
T, Åsberg A, Sandbu R. Significantly increased systemic exposure of
atorvastatin following biliopancreatic diversion with duodenal switch. Clin
Pharm Ther 2010; 87(6): 699-705.
152. Åsberg A, Jardine AG, Bignamini AA, Rollag H, Pescovitz MD, Gahlemann CC,
Humar A, Hartmann A. Effects of the immunosuppressive therapy on outcome
of valganciclovir/ganciclovir treatment for CMV disease in transplanted
patients. Am J Transpl 2010; 10: 1881-1888.
153. Amundsen R, Christensen H, Zabihyan B, Åsberg A. Cyclosporine A, but not
tacrolimus, shows relevant inhibition of OATP1B1 mediated transport of
atorvastatin. Drug Met Disp 2010, 38: 1499-1504.
14
PK-group | 11. February 2011
154. Ellesat KS, Tollefsen K-E, Åsberg A, Thomas KV, Hylland K. Cytotoxicity of
atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss)
hepatocytes. Tox in Vitro 2010; 24: 1610-1618.
155. Narwal R, Akhlaghi F, Åsberg A, Hermann M, Rosenbaum SE. Development of
a population pharmacokinetic model for atorvastatin acid and its lactone
metabolite. Clin Pharmacokin 2010; 40(19): 693-702.
156. Loftheim H, Åsberg A, Reubsaet L. Accelerated 18O-labeling in urinary
proteomics. J Chrom A 2010, 1217: 8241-8248.
157. Åsberg A. Dosing of drugs in patients with reduced renal function
[Norwegian]. Journal of the Norwegian Pharmaceutical Association 2010; 4:
22-24.
158. Skottheim IB, Bogsrud MP, Åsberg A. Statin induced myotoxicity – what do we
know and how is it diagnosed? [Norwegian]. Journal of the Norwegian
Pharmaceutical Association 2010; 7-8: 22-25.
159. Åsberg A, Bergan S. Clinical trials in solid organ transplant recipients –
researcher initiated trials [Norwegian]. Journal of the Norwegian
Pharmaceutical Association 2010; 12: 20-23.
160. Molden E, Okkenhaug C, Solberg E. Increased frequency of CYP2C9 variant
alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with
excessive INR response. Eur J Clin Pharmacol 2010; 66: 525-30.
161. Juliebø, V., Krogseth, M., Skovlund, E., Engedal, K., and Wyller, T.B. (2010)
Medical treatment predicts mortality after hip fracture. J Gerontol A Biol Sci
Med Sci, 65, 442-449. (doi:10:1093/gerona/glp199)
162. Bruheim, K., Guren, M.G., Skovlund, E., Hjermstad, M., Dahl, O., Frykholm, G.,
Carlsen, E., and Tveit, K.M. Late Side Effects and Quality of Life After
Radiotherapy for Rectal Cancer. Int J Rad Oncol Biol Phys 2010; 76: 10051011.
163. Bruheim, K., Guren, M.G., Dahl, A.A., Skovlund, E., Balteskard, L., Carlsen, E.,
Fosså, S.D., and Tveit, K.M. Sexual function in males after radiotherapy for
rectal cancer. Int J Rad Oncol Biol Phys 2010 76: 1012-1017.
164. Skovlund, E. A non-parametric two-sample comparison for skewed data with
unequal variances. J Clin Epidemiol 2010; 63: 594-595.
165. Juliebø, V., Krogseth, M., Skovlund, E., Engedal, K, Ranhoff, A.H., Wyller, T.B.
Delirium is not associated with mortality in elderly hip fracture patients.
Dement Geriatr Cogn Disord 2010; 30: 112-120.
166. Bruheim, K., Tveit, K.M., Skovlund, E., Balteskard, L., Carlsen, E., Fosså, S.D.,
and Guren, M.G. Sexual function in females after radiotherapy for rectal
cancer. Acta Oncologica 2010; 49: 826-832.
15
PK-group | 11. February 2011
167. Kristjansson, S.R., Nesbakken, A., Jordhøy, M., Skovlund, E., Audisio, R.A.,
Johannessen, H.O., Bakka, A., and Wyller, T.B. Comprehensive geriatric
assessment can predict complications in elderly patients after elective surgery
for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol
Hematol 2010; 76: 208-217.
168. Kristjansson, S.R., Jordhøy, M.S., Nesbakken, A., Skovlund, E., Bakka, A.,
Johannessen, H.O., and Wyller, T.B. Which elements of a comprehensive
geriatric assessment (CGA) predict post-operative complications and early
mortality after colorectal cancer surgery in the elderly? J Geriatric Oncol 2010;
1: 57-65.
169. Gravanis, I., Ersbøll, J., Skovlund, E., Abadie, E., Marty, M., and Pignatti, F. The
European Medicines Agency approval of ofatumumab (Arzerra) for the
treatment of chronic lymphocytic leukaemia (CLL) in patients refractory to
fludarabine and alemtuzumab: Summary of the scientific assessment of the
European Medicines Agency (EMA) Committee for Medicinal Products for
Human Use (CHMP). The Oncologist 2010; 15: 1335-1343.
170. Rønning, B., Kristjansson, S.R., Seljeflot, I., Jordhøy, M., Nesbakken, A.,
Skovlund, E., and Wyller, T.B. Frailty measures, inflammatory biomarkers, and
postoperative complications in older surgical patients. Age and Ageing 2010;
39: 758-761
2011
171. Lisboa LF, Åsberg A, Kumar D, Pang X, Hartmann A, Preiksaitis J, Pescovitz MD,
Rollag H, Jardine AG, Humar A. The Clinical Utility of Whole Blood vs. Plasma
CMV Viral Loads Assays for Monitoring Therapeutic Response. Transplantation
2011; 91: 231-236.
172. Gjerset, G.M., Fosså, S.D., Courneya, K.S., Skovlund, E., Jacobsen, A.B., and
Thorsen, L. Interest and preferences for exercise counselling and
programming among Norwegian cancer survivors. Eur J Cancer Care 2011; 20:
96-105.
173. Thorsen, L., Gjerset, G.M., Loge, J.H., Kiserud, C.E., Skovlund, E., Fløtten, T.,
and Fosså, S.D. Cancer patients’ need for rehabilitation services. Acta
Oncologica 2011; 50: 212-222.
174. Christensen H, Hestad AL, Molden E, Mathiesen L. CYP3A5-mediated
metabolism of midazolam in recombinant systems is highly sensitive to
NADPH-cytochrome P450 reductase activity. Xenobiotica 2011; 41 (1): 1-5.
16